Nonetheless, despite the large number of available STING agonists which have been already tested in type I, II and III clinical trials in the treatment of different type of tumours (Zhang et al., 2022b), no antiviral treatment targeting STING has reached clinical trials up to now. This evidence concerns the gene STING1 and neoplasm.